Clinical trial update: focus on the ONTARGET study

por Fitchett, David
Publicado 2007

Results of the ONTARGET and TRANSCEND studies: an update and discussion

por Fitchett, David
Publicado 2009

Potential role of rivaroxaban in patients with acute coronary syndrome

por Fitchett, David H
Publicado 2012

Empagliflozin and Cardio-renal Outcomes in Patients with Type 2 Diabetes and Cardiovascular Disease – Implications for Clinical Practice

por Fitchett, David H
Publicado 2018

Empagliflozin is associated with improvements in liver enzymes potentially consistent with reductions in liver fat: results from randomised trials including the EMPA-REG OUTCOME® t...

por Sattar, Naveed, Fitchett, David, Hantel, Stefan, George, Jyothis T., Zinman, Bernard
Publicado 2018

Empagliflozin reduces cardiovascular events, mortality and renal events in participants with type 2 diabetes after coronary artery bypass graft surgery: subanalysis of the EMPA-REG...

por Verma, Subodh, Mazer, C. David, Fitchett, David, Inzucchi, Silvio E., Pfarr, Egon, George, Jyothis T., Zinman, Bernard
Publicado 2018

Cardiovascular outcomes and LDL-cholesterol levels in EMPA-REG OUTCOME(®)

por Langslet, Gisle, Zinman, Bernard, Wanner, Christoph, Hantel, Stefan, Espadero, Rosa-Maria, Fitchett, David, Johansen, Odd Erik
Publicado 2020

Relationship between hypoglycaemia, cardiovascular outcomes, and empagliflozin treatment in the EMPA-REG OUTCOME(®) trial

por Fitchett, David, Inzucchi, Silvio E, Wanner, Christoph, Mattheus, Michaela, George, Jyothis T, Vedin, Ola, Zinman, Bernard, Johansen, Odd Erik
Publicado 2020

Cardiovascular Benefit of Empagliflozin Across the Spectrum of Cardiovascular Risk Factor Control in the EMPA-REG OUTCOME Trial

por Inzucchi, Silvio E, Khunti, Kamlesh, Fitchett, David H, Wanner, Christoph, Mattheus, Michaela, George, Jyothis T, Ofstad, Anne Pernille, Zinman, Bernard
Publicado 2020

Early benefits of empagliflozin in patients with or without heart failure: findings from EMPA‐REG OUTCOME

por Pellicori, Pierpaolo, Ofstad, Anne Pernille, Fitchett, David, Zeller, Cordula, Wanner, Christoph, George, Jyothis, Zinman, Bernard, Brueckmann, Martina, Lindenfeld, JoAnn
Publicado 2020

Metabolic syndrome in patients with type 2 diabetes and atherosclerotic cardiovascular disease: a post hoc analyses of the EMPA-REG OUTCOME trial

por Ferreira, João Pedro, Verma, Subodh, Fitchett, David, Ofstad, Anne Pernille, Lauer, Sabine, Zwiener, Isabella, George, Jyothis, Wanner, Christoph, Zinman, Bernard, Inzucchi, Silvio E.
Publicado 2020

Generalizability of REDUCE-IT eligibility criteria in a large diabetes cardiovascular outcomes trial: A post hoc subgroup analysis of EMPA-REG outcome: Analysis of EMPA-REG OUTCOME...

por Verma, Subodh, Kosmopoulos, Andrew, Bhatt, Deepak L., Fitchett, David, Ofstad, Anne Pernille, Wanner, Christoph, Mattheus, Michaela, Zinman, Bernard, Lawler, Patrick R., Leiter, Lawrence A.
Publicado 2023

SGLT-2 inhibitors and cardiovascular risk: Proposed pathways and review of ongoing outcome trials

por Inzucchi, Silvio E, Zinman, Bernard, Wanner, Christoph, Ferrari, Roberto, Fitchett, David, Hantel, Stefan, Espadero, Rosa-Maria, Woerle, Hans-Jürgen, Broedl, Uli C, Johansen, Odd Erik
Publicado 2015

Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME(®) trial

por Fitchett, David, Zinman, Bernard, Wanner, Christoph, Lachin, John M., Hantel, Stefan, Salsali, Afshin, Johansen, Odd Erik, Woerle, Hans J., Broedl, Uli C., Inzucchi, Silvio E.
Publicado 2016

Empagliflozin for Patients With Presumed Resistant Hypertension: A Post Hoc Analysis of the EMPA-REG OUTCOME Trial

por Ferreira, João Pedro, Fitchett, David, Ofstad, Anne Pernille, Kraus, Bettina Johanna, Wanner, Christoph, Zwiener, Isabella, Zinman, Bernard, Lauer, Sabine, George, Jyothis T, Rossignol, Patrick, Zannad, Faiez
Publicado 2020

Update to Evidence-Based Secondary Prevention Strategies After Acute Coronary Syndrome

por Fitchett, David H., Leiter, Lawrence A., Lin, Peter, Pickering, Jennifer, Welsh, Robert, Stone, James, Gregoire, Jean, McFarlane, Philip, Langer, Anatoly, Gupta, Anil, Goodman, Shaun G.
Publicado 2020

Time to cardiovascular benefits of empagliflozin: a post hoc observation from the EMPA‐REG OUTCOME trial

por Verma, Subodh, Leiter, Lawrence A., Zinman, Bernard, Sharma, Abhinav, Mattheus, Michaela, Fitchett, David, George, Jyothis, Ofstad, Anne Pernille, Kosiborod, Mikhail N., Wanner, Christoph, Inzucchi, Silvio E.
Publicado 2021

Empagliflozin reduces the risk of mortality and hospitalization for heart failure across Thrombolysis In Myocardial Infarction Risk Score for Heart Failure in Diabetes categories:...

por Verma, Subodh, Sharma, Abhinav, Zinman, Bernard, Ofstad, Anne Pernille, Fitchett, David, Brueckmann, Martina, Wanner, Christoph, Zwiener, Isabella, George, Jyothis T., Inzucchi, Silvio E., Butler, Javed, Mazer, C. David
Publicado 2020

Cardio/Kidney Composite End Points: A Post Hoc Analysis of the EMPA‐REG OUTCOME Trial

por Ferreira, João Pedro, Kraus, Bettina Johanna, Zwiener, Isabella, Lauer, Sabine, Zinman, Bernard, Fitchett, David H., Koitka‐Weber, Audrey, George, Jyothis T., Ofstad, Anne Pernille, Wanner, Christoph, Zannad, Faiez
Publicado 2021

Effects of empagliflozin on insulin initiation or intensification in patients with type 2 diabetes and cardiovascular disease: Findings from the EMPA‐REG OUTCOME trial

por Vaduganathan, Muthiah, Inzucchi, Silvio E., Sattar, Naveed, Fitchett, David H., Ofstad, Anne Pernille, Brueckmann, Martina, George, Jyothis T., Verma, Subodh, Mattheus, Michaela, Wanner, Christoph, Zinman, Bernard, Butler, Javed
Publicado 2021